What is the price target for AbbVie stock after the deal?

The model fair value remains at $253.55, but analysts are split.

Why is AbbVie acquiring Apogee?

To strengthen its immunology and atopic dermatitis pipeline.

Are there regulatory concerns about the deal?

The deal may face regulatory review if it is seen as reducing competition.

AbbVie's Apogee Acquisition Splits Analyst Views on Stock Target

AbbVie (ABBV) announced the acquisition of Apogee Therapeutics for $10.9 billion. The deal has split analyst opinions on the stock's fair value, with some highlighting the atopic dermatitis opportunity and others questioning value capture against competition.

June 24, 2026

2 min read

Source: Simply Wall St.

Key Numbers

deal value

10.9B

fair value

253.55

AbbVie (ABBV) announced the acquisition of Apogee Therapeutics in a deal valued at $10.9 billion. The acquisition has created a split among analysts regarding the stock's price target, with the model fair value remaining at $253.55 per share.

Deal Details

Value: $10.9 billion
Target: Apogee Therapeutics
Sector: Immunology and atopic dermatitis treatments

Rationale

AbbVie aims to bolster its immunology pipeline, particularly in atopic dermatitis (eczema), a rapidly growing market. Apogee has promising drug candidates in late-stage development.

Regulatory Hurdles

The deal is subject to regulatory review and may face scrutiny if regulators believe it reduces competition in the immunology space.

Impact on Stock

The announcement has led to a split among analysts. Some have raised their price targets based on new opportunities, while others have lowered them due to cost concerns and rising competition. ABBV shares are trading flat compared to yesterday's close.

Frequently Asked Questions

The deal is valued at $10.9 billion.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.